Andrew Butcher is speaking on “Balancing cost effectiveness with economics – alleviate funding constraints on HTA approved drugs by managing diverging stakeholder perspectives.” CRA is also sponsoring the conference.
For more information on the event, click here.
Assessing the economic case for Alzheimer’s disease policy prioritisation
The analysis has highlighted specific areas where more urgent action is needed, specifically: Accelerating diagnosing patients at scale; Supporting expansion...